INVO Fertility (NASDAQ:IVF) Issues Earnings Results

INVO Fertility (NASDAQ:IVFGet Free Report) posted its quarterly earnings data on Friday. The company reported $0.35 earnings per share for the quarter, Zacks reports. INVO Fertility had a negative net margin of 183.75% and a negative return on equity of 420.62%.

INVO Fertility Stock Up 0.2%

NASDAQ IVF traded up $0.00 during trading hours on Friday, hitting $0.97. The company had a trading volume of 48,505 shares, compared to its average volume of 78,813. The firm’s 50 day moving average is $1.28 and its 200 day moving average is $2.63. The company has a quick ratio of 0.87, a current ratio of 0.90 and a debt-to-equity ratio of 0.05. INVO Fertility has a fifty-two week low of $0.90 and a fifty-two week high of $84.40.

Institutional Trading of INVO Fertility

A hedge fund recently bought a new position in INVO Fertility stock. Citadel Advisors LLC acquired a new stake in shares of INVO Fertility, Inc (NASDAQ:IVFFree Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 1.19% of INVO Fertility as of its most recent SEC filing. Institutional investors own 12.02% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, INVO Fertility has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Read Our Latest Stock Report on INVO Fertility

About INVO Fertility

(Get Free Report)

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.

Read More

Earnings History for INVO Fertility (NASDAQ:IVF)

Receive News & Ratings for INVO Fertility Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Fertility and related companies with MarketBeat.com's FREE daily email newsletter.